Multicentre NGS study demonstrates effective virological response in ART-naïve individuals, indicating no need for baseline resistance testing.
Our findings indicate that pre-existing IN and RT DRM, including low-abundance and secondary/polymorphic variants, did not compromise the virological efficacy of dolutegravir-based triple therapy in ART-naïve individuals, supporting the high resistance barrier of dolutegravir and the lack of need for baseline resistance testing.
No takes yet. Share an insight, caveat, or question.
Inciarte et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: